EFX

DRUG2 trials

Sponsors

Akero Therapeutics, Inc

Conditions

NASH - Nonalcoholic Steatohepatitis

Phase 2

A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

CompletedNCT03976401

Akero Therapeutics, IncNASH - Nonalcoholic Steatohepatitis

Start: 2019-05-28End: 2022-01-10Updated: 2022-08-04

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

CompletedNCT05039450

Akero Therapeutics, IncNASH - Nonalcoholic Steatohepatitis

Start: 2021-07-30End: 2025-08-28Updated: 2026-07-21

Related Papers

1294-OR: Efruxifermin Improved Liver Disease and Insulin Sensitivity in Participants with Type 2 Diabetes and Metabolic Dysfunction–Associated Steatohepatitis (MASH) Cirrhosis in the SYMMETRY Trial

Diabetes2026-06-08

Efruxifermin in Compensated Liver Cirrhosis Caused by MASH

New England Journal of Medicine2025-05-0946 citations

Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH

Journal of Hepatology2024-09-2529 citations

Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.

2024-03-0444 citations

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.

2022-08-2364 citations

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial.

2021-07-08244 citations